Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20100615/394961 )
- These results are in line with previous studies on colics and confirmthe benefit of L. reuteri in colicky infants, says Doctor Francesco Savino,Department of Paediatrics, Regina Margherita Children's Hospital, Universityof Turin, Italy.
Advertisement
To view the Multimedia News Release, please click:
http://multivu.prnewswire.com/mnr/prne/biogaia/42443/
In this double blind, placebo controlled study 50 infants with confirmedinfantile colic were randomly assigned to two treatments: L. reuteriProtectis drops 108 CFU per day or placebo for 21 consecutive days.
The primary outcome was a reduction in average crying time to less thanthree hours per day, which is the limit of colic, by day 21. On day 21, 84 %of the L. reuteri Protectis supplemented infants had resolved their colic(dropped to less than three hours of crying), a significantly higher numbercompared to 43% in the placebo group (p<0.05).
At the time of inclusion the median crying time per day was 370 minutesin the probiotic group and 300 minutes in the placebo group. On day seven thecrying time had been reduced by 74 %, to 95 minutes, in the L. reuteriProtectis group and to 185 minutes in the placebo group (p=0.082). At the endof the study there was a significant difference in median daily crying timebetween the groups, 35 minutes in the L. reuteri Protectis group versus 90minutes in the placebo group (p<0.05).
The proportion of infants responding to the supplementation, defined as a50 % or greater reduction in median crying time, was significantly greater inthe L. reuteri Protectis group compared to the placebo group at day 7, 14 and21 of the study.
The study was presented on the Annual Meeting of ESPGHAN in Istanbul onthe 10th of June 2010.
BioGaia is a biotechnology company that develops, markets and sellsprobiotic products with documented health benefits. The products areprimarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri),which has probiotic, health-enhancing effects. The class B share of theParent Company BioGaia AB is quoted on the Small Cap list of the NASDAQ OMXNordic Exchange Stockholm.
http://www.biogaia.com- The data with L. reuteri are convincing and confirm, in a placebo-controlled study, our earlier data with this probiotic. We believe these results will have an impact on the treatment of infants with colic, says Doctor Savino.
SOURCE BioGaia
